Traitement alcalin pour la préservation de la fonction du greffon rénal chez les patients transplantés rénaux

This study focuses on kidney transplant recipients, aiming to find out if a treatment called alkali therapy can help preserve kidney function and slow down the progression of chronic kidney disease. The study is particularly important as it could potentially improve the care and quality of life for individuals who have undergone a kidney transplant. Previous research has suggested that alkali therapy might slow down the worsening of chronic kidney disease. In this study, 300 kidney transplant recipients will participate for a duration of 2 years. They will be randomly assigned to two groups: one group will receive the alkali treatment in the form of a product called Nephrotrans®, while the other group will receive a placebo. The study is designed in such a way that only the researchers, not the participants, will know who is receiving the actual treatment. The main outcome of interest is the change in kidney function, which will be measured using a standard method called the CKD-EPI creatinine equation.